RecruitingPhase 2NCT07541287

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)

Sponsor

Jade Biosciences, Inc.

Enrollment

30 participants

Start Date

May 19, 2026

Study Type

INTERVENTIONAL

Conditions

IgA Nephropathy

Summary

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JADE101 for people with iga nephropathy. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.